CA3133376A1 - Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations - Google Patents
Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations Download PDFInfo
- Publication number
- CA3133376A1 CA3133376A1 CA3133376A CA3133376A CA3133376A1 CA 3133376 A1 CA3133376 A1 CA 3133376A1 CA 3133376 A CA3133376 A CA 3133376A CA 3133376 A CA3133376 A CA 3133376A CA 3133376 A1 CA3133376 A1 CA 3133376A1
- Authority
- CA
- Canada
- Prior art keywords
- leukemia
- compound
- mutation
- flt3
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773686P | 2018-11-30 | 2018-11-30 | |
| US62/773,686 | 2018-11-30 | ||
| PCT/US2019/063993 WO2020113216A1 (en) | 2018-11-30 | 2019-12-02 | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3133376A1 true CA3133376A1 (en) | 2020-06-04 |
Family
ID=70849819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3133376A Pending CA3133376A1 (en) | 2018-11-30 | 2019-12-02 | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200171001A1 (https=) |
| EP (1) | EP3886840A4 (https=) |
| JP (1) | JP2022509257A (https=) |
| KR (1) | KR20210150353A (https=) |
| CN (1) | CN113365622A (https=) |
| AU (1) | AU2019387508A1 (https=) |
| CA (1) | CA3133376A1 (https=) |
| WO (1) | WO2020113216A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PY2125608A (es) * | 2020-04-01 | 2021-12-28 | Fmc Corp | Atropisómeros de derivados de piridazinona como herbicidas |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| DK2940014T3 (en) * | 2012-12-28 | 2018-12-10 | Crystalgenomics Inc | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| EP2971079A1 (en) * | 2013-03-12 | 2016-01-20 | Novartis AG | Markers for isocitrate dehydrogenase inhibitors |
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| HK1255939A1 (zh) * | 2015-08-03 | 2019-09-06 | Gilead Sciences, Inc. | 用於治疗癌症之组合疗法 |
| ES2905915T3 (es) * | 2015-12-04 | 2022-04-12 | Servier Lab | Procedimientos de tratamiento de neoplasias malignas |
| JP6961879B2 (ja) * | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| CA3029851A1 (en) * | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
| WO2018081830A1 (en) * | 2016-10-31 | 2018-05-03 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
| TWI821174B (zh) * | 2017-02-21 | 2023-11-11 | 加拿大商艾普托斯生物科學公司 | 治療血液惡性腫瘤患者的方法 |
-
2019
- 2019-12-02 WO PCT/US2019/063993 patent/WO2020113216A1/en not_active Ceased
- 2019-12-02 US US16/700,426 patent/US20200171001A1/en not_active Abandoned
- 2019-12-02 EP EP19888779.6A patent/EP3886840A4/en not_active Withdrawn
- 2019-12-02 AU AU2019387508A patent/AU2019387508A1/en not_active Abandoned
- 2019-12-02 KR KR1020217019708A patent/KR20210150353A/ko not_active Ceased
- 2019-12-02 CN CN201980090539.1A patent/CN113365622A/zh active Pending
- 2019-12-02 CA CA3133376A patent/CA3133376A1/en active Pending
- 2019-12-02 JP JP2021530883A patent/JP2022509257A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020113216A1 (en) | 2020-06-04 |
| EP3886840A4 (en) | 2022-08-24 |
| EP3886840A1 (en) | 2021-10-06 |
| US20200171001A1 (en) | 2020-06-04 |
| CN113365622A (zh) | 2021-09-07 |
| JP2022509257A (ja) | 2022-01-20 |
| AU2019387508A1 (en) | 2021-06-10 |
| KR20210150353A (ko) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022252696B2 (en) | Methods for treating patients with hematologic malignancies | |
| KR102806778B1 (ko) | Erbb 수용체 억제제 | |
| US10106538B2 (en) | Inhibitors of protein kinases | |
| CN103648500B (zh) | 双功能酶制钳型分子的方法和用途 | |
| US20200171001A1 (en) | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations | |
| WO2017222930A1 (en) | Therapeutic compounds | |
| KR102917552B1 (ko) | 프로스타글란딘 ep₄ 수용체 길항제 화합물 | |
| US12258315B2 (en) | S6K1 protein kinase inhibitors as cancer therapeutics | |
| EP3176165B1 (en) | Crystal of azole benzene derivative as xanthine oxidase inhibitor | |
| HK40014760A (en) | Methods for treating patients with hematologic malignancies | |
| HK40046084A (en) | Erbb receptor inhibitors | |
| HK40046084B (en) | Erbb receptor inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231201 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250102 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250314 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250314 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250314 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250502 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260113 |